title: Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products.
abstract: Hyperglycemia accelerates the formation and accumulation of advanced glycation end products (AGE) in plasma and tissue, which may cause diabetic vascular complications. We recently reported that scavenger receptors expressed by liver endothelial cells (LECs) dominantly mediate the endocytic uptake of AGE proteins from plasma, suggesting its potential role as an eliminating system for AGE proteins in vivo (Smedsrod, B., Melkko, J., Araki, N., Sano, H., and Horiuchi, S. (1997) Biochem. J. 322, 567-573). In the present study we examined the effects of insulin on macrophage scavenger receptor (MSR)-mediated endocytic uptake of AGE proteins. LECs expressing MSR showed an insulin-sensitive increase of endocytic uptake of AGE-bovine serum albumin (AGE-BSA). Next, RAW 264.7 cells expressing a high amount of MSR were overexpressed with human insulin receptor (HIR). Insulin caused a 3.7-fold increase in endocytic uptake of 125I-AGE-BSA by these cells. The effect of insulin was inhibited by wortmannin, a phosphatidylinositol-3-OH kinase (PI3 kinase) inhibitor. To examine at a molecular level the relationship between insulin signal and MSR function, Chinese hamster ovary (CHO) cells expressing a negligible level of MSR were cotransfected with both MSR and HIR. Insulin caused a 1.7-fold increase in the endocytic degradation of 125I-AGE-BSA by these cells, the effect of which was also inhibited by wortmannin and LY294002, another PI3 kinase inhibitor. Transfection of CHO cells overexpressing MSR with two HIR mutants, a kinase-deficient mutant, and another lacking the binding site for insulin receptor substrates (IRS) resulted in disappearance of the stimulatory effect of insulin on endocytic uptake of AGE proteins. The present results indicate that insulin may accelerate MSR-mediated endocytic uptake of AGE proteins through an IRS/PI3 kinase pathway.
authors.affiliation: Department of Biochemistry, Kumamoto University School of Medicine, Honjo 2-2-1, Kumamoto 860-0811, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sano
authors.forename: T
authors.initials: T
authors.lastname: Higashi
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: J
authors.initials: J
authors.lastname: Melkko
authors.forename: Y
authors.initials: Y
authors.lastname: Jinnouchi
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: Y
authors.initials: Y
authors.lastname: Ebina
authors.forename: H
authors.initials: H
authors.lastname: Makino
authors.forename: B
authors.initials: B
authors.lastname: Smedsrod
authors.forename: S
authors.initials: S
authors.lastname: Horiuchi
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells; D002460:Cell Line; D002478:Cells, Cultured; D002867:Chromones / Q000494:pharmacology; D006224:Cricetinae; D004705:Endocytosis / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017127:Glycation End Products, Advanced / Q000493:pharmacokinetics*; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D007700:Kinetics; D008077:Lipoproteins, LDL / Q000493:pharmacokinetics; D008099:Liver / Q000502:physiology; D008264:Macrophages / Q000187:drug effects / Q000502:physiology*; D008565:Membrane Proteins; D008954:Models, Biological; D009025:Morpholines / Q000494:pharmacology; D011090:Polyenes / Q000494:pharmacology; D051381:Rats; D011972:Receptor, Insulin / Q000096:biosynthesis / Q000502:physiology*; D011971:Receptors, Immunologic / Q000187:drug effects / Q000502:physiology*; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D051122:Scavenger Receptors, Class B; D012710:Serum Albumin, Bovine / Q000493:pharmacokinetics*; D020123:Sirolimus; D014162:Transfection; D000077191:Wortmannin
chemical_list: D000730:Androstadienes; D002867:Chromones; D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D007328:Insulin; D008077:Lipoproteins, LDL; D008565:Membrane Proteins; D009025:Morpholines; D011090:Polyenes; D011971:Receptors, Immunologic; D018110:Receptors, Lipoprotein; D051116:Receptors, Scavenger; D011993:Recombinant Fusion Proteins; C454739:Scarb1 protein, mouse; D051122:Scavenger Receptors, Class B; C032629:acetyl-LDL; C081628:advanced glycation end products-bovine serum albumin; D012710:Serum Albumin, Bovine; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D011972:Receptor, Insulin; D020123:Sirolimus; D000077191:Wortmannin